Project BI 1199.247

Basic data

Title:
BI 1199.247
Duration:
09/06/2017 to 30/09/2023
Abstract / short description:
A double blind, randomized, placebo-controlled trial evaluating
the efficacy and safety of nintedanib over 52 weeks in patients
with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Ingelheim am Rhein, Rheinland-Pfalz, Germany
Help

will be deleted permanently. This cannot be undone.